Skip to content
Retatrutide Legal

Papers behind the claims you read

What retatrutide papers let you check for yourself

Eli Lilly developed retatrutide hoping to improve weight and diabetes care. The numbered papers let you trace the reported changes to their source.

Return to the measured findings

How paper numbers help you find the original claim

These 15 papers support the findings on Retatrutide references and the other pages. Match a claim's bracketed number to the paper below, then follow the link to read more.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. et al. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption. J Clin Med. 2025. ↗
  8. Melson E, et al. What is the pipeline for future medications for obesity? International Journal of Obesity. 2025;49(3):433-451. ↗
  9. Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj metabolic health and disease. 2024;2(1):31. ↗
  10. Deravi M, et al. The 'Weight' for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. Journal of Pharmacy Technology. 2024;40(6):300-305. ↗
  11. Kusminski CM, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829-3853. ↗
  12. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. ↗
  13. Lempesis IG, et al. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabolism Open. 2026. ↗
  14. et al. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, and the Path Forward. Cureus. 2026. ↗
  15. Elmendorf AJ, et al. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research. 2026. ↗